摘要
目的探讨低分子肝素与局部枸橼酸抗凝方案用于危重症患者连续性肾脏替代治疗效果差异。方法研究对象随机选取该院2015年1月—2016年12月收治行连续性肾脏替代治疗治疗危重症患者共100例,以随机数字表法分为对照组(50例)和观察组(50例),分别行低分子肝素与局部枸橼酸抗凝;比较两组患者抗凝有效性、治疗前后凝血功能指标及出血事件发生率等。结果对照组抗凝有效0级、I级、II级及III级比例分别为32.00%,44.00%,16.00%,4.00%;观察组抗凝有效0级、I级、II级及III级比例分别为54.00%,40.00%,6.00%,0.00%;观察组患者抗凝有效性明显优于对照组(P<0.05);观察组患者治疗后APTT水平均明显高于对照组、治疗前(P<0.05);但两组患者治疗后PLT水平比较差异无统计学意义(P>0.05);同时两组患者出血事件发生率比较差异无统计学意义(P>0.05)。结论相较于低分子肝素,局部枸橼酸抗凝方案用于危重症患者连续性肾脏替代治疗可显著改善抗凝效果,延长APTT时间,且未导致出血事件发生风险上升。
Objective To discuss the difference in the effect of low molecular heparin and local citric acid anticoagulant plan in the replacement therapy of continuous kidney of critically ill patients. Methods 100 cases of critically ill patients with continuous kidney therapy admitted and treated in our hospital from January 2015 to December 2016 were selected and randomly divided into two groups with 50 cases in each, respectively treated with low molecular heparin and local citric acid anticoagulant plan, and the effectiveness, anticoagulant function indexes before and after treatment and incidence rate of bleeding events were compared between the two groups. Results The ratios of effective 0 level, I level, II level and III level in the observation group were better than those in the control group(32.00%,44.00%,16.00%,4.00% vs 54.00%,40.00%,6.00%,0.00%)(P<0.05), after treatment, the APTT level in the observation group was obviously higher than that in the control group and that before treatment(P<0.05), but the difference in the PLT level between the two groups was not obvious(P>0.05), at the same time, the difference in the incidence rate of bleeding events between the two groups was not obvious(P>0.05). Conclusion The local citric acid anticoagulant plan in the critically ill patients with continuous kidney can obviously improve the anticoagulant effect, prolong the APTT time and does not cause the increase of occurrence risks.
出处
《中外医疗》
2017年第20期113-115,共3页
China & Foreign Medical Treatment
关键词
连续性肾脏替代治疗
低分子肝素
枸橼酸
危重症
Replacement therapy of continuous kidney of critically ill patients
Low molecular heparin
Citric acid
Critically ill
